# Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer

> **NCT01579188** · PHASE3 · UNKNOWN · sponsor: **Kael-GemVax Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Inoperable Stage III Non-small Cell Lung Cancer

## Interventions

- **DRUG:** GV1001
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT01579188
- **Lead sponsor:** Kael-GemVax Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2012-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579188, "Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01579188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*